文献速递浆细胞疾病造血干细胞移植与细胞治疗

多发性骨髓瘤自体移植后MASS-FIX检测血清单克隆蛋白的意义

Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma.
PubMed 文献 · Br J Haematol · 2020-11-20

本研究评估了多发性骨髓瘤患者自体干细胞移植(ASCT)后,联合使用骨髓二代流式(NGF)和血清MASS-FIX检测微小残留病(MRD)的价值。在61例移植后约100天NGF阴性完全缓解患者中,59%为MASS-FIX阳性;MASS-FIX作为简便的血液检测可补充骨髓NGF,更准确地进行预后分层。

要点

  • ASCT后NGF阴性患者中约六成MASS-FIX阳性,提示存在骨髓外残留。
  • MASS-FIX阳性/NGF阴性患者无进展生存率显著低于双阴性患者。
  • MASS-FIX可补充骨髓NGF,提升MRD评估的预后准确性。

核心结论

  • MASS-FIX作为基于外周血的简易检测,可补充骨髓NGF,更准确地对骨髓瘤患者进行预后判断。

研究设计与样本

  • 研究纳入61例多发性骨髓瘤患者,均为ASCT后约100天达到完全缓解且NGF检测MRD阴性。
  • 同时采用NGF和MASS-FIX评估MRD,中位随访26个月。

主要发现

  • 61例NGF阴性完全缓解患者中,59%为MASS-FIX阳性。

临床怎么用

  • 对于ASCT后NGF阴性的骨髓瘤患者,可考虑联合MASS-FIX检测血清单克隆蛋白以发现潜在残留病。
  • MASS-FIX阳性/NGF阴性提示预后较差,可能需要更密切监测或干预。

局限性

  • 样本量较小(61例),随访时间较短(中位26个月),需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Measurable residual disease (MRD) assessment by marrow-based next-generation flow cytometry (NGF) following autologous stem cell transplantation (ASCT) may lead to false-negative results due to patchy marrow involvement and extramedullary disease in patients with multiple myeloma. We assessed the value of simultaneous MRD evaluation with NGF and serum matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MASS-FIX). Of all 61 complete responders who were NGF-negative for MRD, around day-100 post ASCT, 59% were MASS-FIX-positive. At median follow-up of 26 months, 69% of MASS-FIX(+)/NGF(-) patients were alive and progression-free versus 96% of MASS-FIX(-)/NGF(-) patients, P = 0·02. MASS-FIX, a simple peripheral blood-based assay complements marrow-based NGF to accurately prognosticate patients with myeloma.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Abeykoon JP, Murray DL, Murray I, et al. Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. Br J Haematol. 2020. PMID: 33216966. doi:10.1111/bjh.17195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。